HSBC TUR.WAR.OP.END. RGO/ DE000HS37RH3 /
| 2024-09-05 9:36:11 PM | Chg.-0.2600 | Bid9:59:40 PM | Ask9:59:40 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 2.5100EUR | -9.39% | 2.4900 Bid Size: 25,000 |
2.5200 Ask Size: 25,000 |
Regeneron Pharmaceut... | 876.7267 USD | 2078-12-31 | Call |
GlobeNewswire
08-26
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Fol...
GlobeNewswire
08-26
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire
08-15
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
08-15
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimi...
GlobeNewswire
08-12
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...
GlobeNewswire
08-08
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company ...
GlobeNewswire
08-07
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
GlobeNewswire
07-31
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
GlobeNewswire
07-23
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire
07-23
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
GlobeNewswire
07-16
Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
GlobeNewswire
07-10
Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
GlobeNewswire
07-07
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
07-03
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...
GlobeNewswire
07-03
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
GlobeNewswire
06-30
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
06-28
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...
GlobeNewswire
06-27
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...
GlobeNewswire
06-26
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...
